Beigene, Ltd. (NASDAQ:ONC) Insider Sells $34,620.24 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Titus B. Ball sold 134 shares of the company’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $258.36, for a total value of $34,620.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Beigene Stock Up 5.4%

Beigene stock opened at $276.53 on Friday. The business’s 50-day moving average is $240.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The firm has a market capitalization of $32.74 billion, a price-to-earnings ratio of -33.56, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. Beigene, Ltd. has a 52 week low of $141.31 and a 52 week high of $287.88.

Beigene (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. Equities analysts expect that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen upgraded Beigene from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and upped their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. JMP Securities set a $348.00 price target on shares of Beigene in a research report on Friday, February 28th. Guggenheim lifted their price objective on shares of Beigene from $348.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Finally, Royal Bank of Canada cut their price objective on shares of Beigene from $312.00 to $311.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $319.00.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.